Phase II trial of old age acute myeloid leukemia treatment by arsenic trioxide and low-dose subcutaneous cytosin arabinoside.

7075 Background: AML is a disease of old age, but unfortunately due to several factors standard treatment can not be delivered to these patients. Here we tried to achieve to bet possible response to these patients. METHODS Eleven old age patients selected for this trial. Patients couldn't tolerate standard treatment of AML due to old age or comorbid… CONTINUE READING